Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy
- PMID: 18304619
- PMCID: PMC2603620
- DOI: 10.1016/j.urology.2007.10.055
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy
Abstract
Objectives: Men with pathologically organ-confined, Gleason score 6 or less prostate cancer are considered to have an excellent prognosis after surgery as definitive monotherapy. We determined the incidence of biochemical recurrence (BR), local recurrence (LR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM) among this low-risk cohort.
Methods: A retrospective search of our radical prostatectomy database identified 6081 men with pathologically organ-confined (pT2), Gleason score 6 or less prostate cancer treated from 1983 to 2005. Of these, 2551 (42%) had adequate follow-up information and were assessed for BR, LR, DM, and PCSM. The pathologic specimens of men with disease progression were reevaluated by an experienced genitourinary pathologist, and the patients with disease that was upgraded or upstaged (n = 25) were excluded from additional analysis, resulting in a final study cohort of 2526. The actuarial probabilities of BR and LR were estimated using the Kaplan-Meier method.
Results: With a median follow-up of 5.0 years (range 2 to 22), BR occurred in 13 patients (0.5%). The 5, 10, and 15-year actuarial probability of BR was 0.3%, 0.9%, and 1.3%, respectively. Five patients (0.2%) developed LR, four of whom received salvage radiotherapy with a subsequently undetectable prostate-specific antigen level. The 5, 10, and 15-year actuarial probability of LR was 0.1%, 0.5%, and 0.5%, respectively. No DM or PCSM occurred.
Conclusions: With postoperative follow-up for more than 2500 patients with pathologically organ-confined, Gleason score 6 or less prostate cancer, BR and LR after radical prostatectomy were extremely rare, and no patients experienced DM or PCSM.
Similar articles
-
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4. BJU Int. 2013. PMID: 22487441
-
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.Mayo Clin Proc. 2001 Jun;76(6):576-81. doi: 10.4065/76.6.576. Mayo Clin Proc. 2001. PMID: 11393495
-
Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.Clin Prostate Cancer. 2003 Mar;1(4):242-7. doi: 10.3816/cgc.2003.n.006. Clin Prostate Cancer. 2003. PMID: 15040883
-
The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy.Int J Clin Oncol. 2020 Feb;25(2):377-383. doi: 10.1007/s10147-019-01561-4. Epub 2019 Oct 31. Int J Clin Oncol. 2020. PMID: 31673831
-
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.Urol Clin North Am. 2001 Aug;28(3):555-65. doi: 10.1016/s0094-0143(05)70163-4. Urol Clin North Am. 2001. PMID: 11590814 Review.
Cited by
-
The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):57-64. doi: 10.1158/1055-9965.EPI-08-0377. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19124481 Free PMC article.
-
Epigenetic alterations in human prostate cancers.Endocrinology. 2009 Sep;150(9):3991-4002. doi: 10.1210/en.2009-0573. Epub 2009 Jun 11. Endocrinology. 2009. PMID: 19520778 Free PMC article. Review.
-
Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.Histopathology. 2020 Apr;76(5):755-762. doi: 10.1111/his.14064. Histopathology. 2020. PMID: 31944367 Free PMC article.
-
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a030445. doi: 10.1101/cshperspect.a030445. Cold Spring Harb Perspect Med. 2019. PMID: 29959132 Free PMC article. Review.
-
Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?Can Urol Assoc J. 2014 Jan-Feb;8(1-2):47-52. doi: 10.5489/cuaj.751. Can Urol Assoc J. 2014. PMID: 24578745 Free PMC article.
References
-
- Tornblom M, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004;108:122–129. - PubMed
-
- Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–878. - PubMed
-
- Han M, Partin AW, Chan DY, et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol. 2004;171:23–26. - PubMed
-
- Lerner SE, Blute ML, Bergstralh EJ, et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996;156:137–143. - PubMed
-
- Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866–871. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical